Literature DB >> 3964171

Scopolamine effects on memory retention in mice: a model of dementia?

J F Flood, A Cherkin.   

Abstract

Scopolamine-treated normal young human subjects exhibit memory dysfunctions analogous to those observed in demented patients. The dysfunctions are reversible by physostigmine but not by d-amphetamine which suggests that the memory impairment is specifically related to reduced cholinergic transmission caused by scopolamine. Scopolamine-induced amnesia has been proposed as a model for dementia where reduced cholinergic function is the suspected cause. We report seven experiments in young adult mice which examine scopolamine's effects on memory retention and whether its amnestic effects are specifically blocked by cholinergic agonists or cholinomimetics. Young adult mice were trained to avoid footshock in a T maze and their retention tested 1 week after training. Pretraining subcutaneous injection of scopolamine improved retention scores of "undertrained" mice at a dose of 0.01 mg/kg but impaired at a dose of 0.1 mg/kg. Post-training injection showed no effect at 0.01 mg/kg, enhanced retention scores at 0.1 mg/kg, and impaired at 1.0 mg/kg. The impairment by 1.0 mg/kg was blocked by injection 45 min post-training of each of two cholinergic drugs but was also counteracted by six drugs which act upon five other neural systems (catecholamine, serotonin, glycine, GABA, and hormonal). When scopolamine was injected 40 min pretraining, and each of eight drugs was injected immediately after training, the amnestic effect of scopolamine was only partially counteracted. This suggests that scopolamine impaired acquisition, in addition to some impairment of memory processing. This was confirmed by a direct study of acquisition rates of the avoidance response; 0.1 mg/kg of scopolamine impaired acquisition. The overall results indicate that pretraining administration of scopolamine impairs learning and to some degree memory processing. Counteracting scopolamine-induced amnesia, by either pretraining or post-training drug administration, is not specific to the cholinergic system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3964171     DOI: 10.1016/s0163-1047(86)90750-8

Source DB:  PubMed          Journal:  Behav Neural Biol        ISSN: 0163-1047


  35 in total

Review 1.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  RU 41,656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers.

Authors:  A Patat; M J Klein; A Surjus; M Hucher; J Granier
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Memory modulation with peripherally acting cholinergic drugs.

Authors:  D K Rush; K Streit
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Modulation of the transmission of signals of the rabbit septum in the presence of influences on the cholinergic system.

Authors:  E S Brazhnik; O S Vinogradova
Journal:  Neurosci Behav Physiol       Date:  1989 May-Jun

6.  Chronic Administration of Scopolamine Increased GSK3βP9, Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats.

Authors:  Maricarmen Hernández-Rodríguez; Ivonne Maciel Arciniega-Martínez; Iohanan Daniel García-Marín; José Correa-Basurto; Martha Cecilia Rosales-Hernández
Journal:  Mol Neurobiol       Date:  2020-07-07       Impact factor: 5.590

7.  Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects.

Authors:  E Wezenberg; R J Verkes; B G C Sabbe; G S F Ruigt; W Hulstijn
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 8.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

9.  Similar ameliorating effects of benzomorphans and 5-HT2 antagonists on drug-induced impairment of passive avoidance response in mice: comparison with acetylcholinesterase inhibitors.

Authors:  K Matsuno; T Senda; K Matsunaga; S Mita; H Kaneto
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Cholinergic and dopaminergic agents which inhibit a passive avoidance response attenuate the paradigm-specific increases in NCAM sialylation state.

Authors:  E Doyle; C M Regan
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.